ICCC

Business Context and Reporting Period

Company: ImmuCell Corporation (ICCC)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: An animal health biologics company focused on neonatal dairy and beef calves. The primary product line is First Defense® (veterinary biologics and feed supplements). The company recently ceased efforts to obtain FDA approval for its Re-Tain® product and is repurposing the associated manufacturing facility to expand First Defense® production capacity.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Product sales increased 20.9% year-over-year (YoY) for the six months ended June 30, 2026, driven by higher volumes and price increases in the First Defense® line. Domestic sales rose 32.5%, while international sales declined 35.7%.
• Profitability Surge: Net income increased 93.8% YoY. This was significantly boosted by a $2.0 million settlement recorded as "Other operating income" from a former contract manufacturer regarding Re-Tain® development costs.
• Expense Shifts: Product development expenses decreased 72.5% YoY. This reduction is largely due to the strategic decision to cease Re-Tain® FDA approval efforts, shifting associated facility depreciation and building costs from R&D to Cost of Goods Sold (COGS).
• COGS Pressure: COGS increased 25.3% YoY, outpacing revenue growth. This was caused by the aforementioned cost reclassification, increased raw material costs, and manufacturing inefficiencies during the transition period.
• Liquidity Improvement: Cash and cash equivalents increased by $5.05 million (133%) compared to the prior year-end, supported by strong operating cash flows.

Guidance, Outlook, and Risks

• Manufacturing Expansion: The Board authorized a two-phase capacity expansion program to refit the former Re-Tain® facility for First Defense® production.
  • Phase 1: Renovate facility and add a new freeze dryer; estimated cost $3.5 million; duration ~12 months.
  • Phase 2: Repurpose equipment and add automation for liquid processing; estimated cost $4.5 million; duration ~6 months.
• Debt Obligations: Total debt outstanding is approximately $8.3 million. The company has a $1.0 million line of credit (LOC) available through September 11, 2026, with no current draw. Weighted average interest rate is 4.29%.
• Subsequent Event: On July 31, 2026, the USDA approved an extension of expiration limits for colostrum. The company expects to release a $233,665 reserve for previously obsolete colostrum in Q3 2026, though the total financial impact is not yet estimable.
• Risks:
  • Production Constraints: Risks of cost overruns, contamination, or delays in the expansion project could lead to supply shortfalls.
  • Supply Chain: Reliance on colostrum collection from farms in a single state creates vulnerability to disease outbreaks or supply refusals.
  • Seasonality: Sales are seasonal, with higher volumes expected in Q1 due to the beef calving season.

Investor Verification Checklist

• Settlement Sustainability: Verify that the $2.0 million settlement income is a one-time event and not indicative of recurring operating performance.
• Expansion Execution: Monitor the timeline and cost adherence of the $8.0 million manufacturing expansion program to ensure it does not strain liquidity.
• Margin Recovery: Track whether gross margins stabilize as the facility transition completes and manufacturing inefficiencies are resolved.
• Customer Concentration: Note that two customers (Company A and Company B) accounted for 66% of sales in the first six months of 2026.
• Debt Covenants: Confirm continued compliance with financial covenants on the $8.3 million debt package secured by substantially all assets.